Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN)

被引：0
|
作者：
Besse, Benjamin
Le Moulec, Sylvestre
Senellart, Helene
Mazieres, Julien
Barlesi, Fabrice
Dansin, Eric
Robinet, Gilles
Perol, Maurice
Moro-Sibilot, Denis
Soria, Jean-Charles
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Val de Grace Hosp, Paris, France
[3] Inst Cancerol Ouest, Nantes, France
[4] Toulouse Univ Hosp, Toulouse, France
[5] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France
[6] Ctr Oscar Lambret, F-59020 Lille, France
[7] CHU Morvan, Inst Cancerol, Brest, France
[8] Ctr Leon Berard, F-69373 Lyon, France
[9] CHU Grenoble, Thorac Oncol Unit, F-38043 Grenoble, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8059
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH 1ST-LINE CHEMOTHERAPY OR 2ND-LINE ERLOTINIB IN NON-SQUAMOUS NSCLC (NS-NSCLC) PATIENTS WITH ASYMPTOMATIC UNTREATED BRAIN METASTASES (ML21823)
    Besse, B.
    Le Moulec, S.
    Senellart, H.
    Mazieres, J.
    Barlesi, F.
    Dansin, E.
    Robinot, G.
    Perol, M.
    Moro-Sibilot, D.
    Soria, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 426 - 427
  • [2] IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
    Socinski, Mark A.
    Nishio, Makoto
    Jotte, Robert M.
    Cappuzzo, Federico
    Orlandi, Francisco
    Stroyakovskiy, Daniil
    Nogami, Naoyuki
    Rodriguez-Abreu, Delvys
    Moro-Sibilot, Denis
    Thomas, Christian A.
    Barlesi, Fabrice
    Finley, Gene
    Kong, Shengchun
    Lee, Anthony
    Coleman, Shelley
    Zou, Wei
    McCleland, Mark
    Shankar, Geetha
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1909 - 1924
  • [3] A phase II study (CTONG0803) of erlotinib as second-line treatment in advanced non-small cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after first-line chemotherapy (CT).
    Wu, Y. L.
    Zhou, C.
    Cheng, Y.
    Lu, S.
    Chen, G.
    Huang, C.
    Huang, Y.
    Yan, H. H.
    Yang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] A POOLED ANALYSIS OF ADVANCED NONSQUAMOUS NSCLC PATIENTS WITH STABLE TREATED BRAIN METASTASES IN TWO PHASE II TRIALS RECEIVING BEVACIZUMAB AND PEMETREXED AS SECOND-LINE THERAPY
    Gubens, Matthew
    Akerley, Wallace
    Lynch, Thomas
    Langer, Corey J.
    Socinski, Mark A.
    Colevas, A. Dimitrios
    Clement-Duchene, Christelle
    Wakelee, Heather
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1224 - S1225
  • [5] Phase II study of bevacizumab, cisplatin, and pemetrexed as first-line chemotherapy for advanced nonsquamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type.
    Murakami, Shuji
    Saito, Haruhiro
    Karino, Fumi
    Kondo, Tetsuro
    Oshita, Fumihiro
    Yamada, Kouzo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC)
    Thomas, M.
    Reuss, A.
    Fischer, J. R.
    Andreas, S.
    Kortsik, C.
    Grah, C.
    Serke, M. H.
    von Eiff, M.
    Witt, C.
    Kollmeier, J.
    Mueller, E.
    Mueller, L.
    Schenk, M.
    Heine, R.
    Behringer, D. M.
    Schroeder, M.
    Reinmuth, N.
    Schnabel, P.
    Acker, T.
    Wolf, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC Results from the Phase IV MO19390 (SAiL) Study
    Tsai, Chun-Ming
    Au, Joseph Siu-kie
    Chang, Gee-Chen
    Cheng, Ashley Chi-kin
    Zhou, Caicun
    Wu, Yi-long
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : 1092 - 1097
  • [8] Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
    Zhang, Li
    Wang, Zhehai
    Fang, Jian
    Yu, Qitao
    Han, Baohui
    Cang, Shundong
    Chen, Gongyan
    Mei, Xiaodong
    Yang, Zhixiong
    Stefaniak, Victoria
    Lin, Yong
    Wang, Shuyan
    Zhang, Wen
    Sun, Luyao
    Yang, Yunpeng
    LUNG CANCER, 2022, 171 : 56 - 60
  • [9] First-line chemotherapy (CT) with pemetrexed (PEM) plus cisplatin (CIS) plus bevacuzimab (BEV) followed by maintenance PEM plus BEV for advanced nonsquamous non-small cell lung cancer (NS-NSCLC): Final results of a single-arm phase II study.
    Hillerdal, Gunnar N.
    Sorensen, Jens Benn
    Hoeffken, Gert
    Favaretto, Adolfo
    Perez-Carrion, Ramon
    Visseren-Grul, Carla
    Ameryckx, Sophie
    Soldatenkova, Victoria
    Bourayou, Nawel
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon α-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results
    Ravaud, Alain
    Barrios, Carlos H.
    Alekseev, Boris Y.
    Tay, Miah Hiang
    Agarwala, Sanjiv S.
    Yalcin, Suayib
    Lin, Chia-Chi
    Shkolnik, Michail
    Matveev, Vsevolod
    Anak, Ozlem
    Gogov, Sven
    Pelov, Diana
    Louveau, Anne-Laure
    Vaury, Alexandra
    Melichar, Bohuslav
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345